VM 100

Drug Profile

VM 100

Alternative Names: VM100

Latest Information Update: 21 Dec 2015

Price : $50

At a glance

  • Originator Vision Medicines
  • Class Eye disorder therapies; Monoclonal antibodies; Small molecules
  • Mechanism of Action Amyloid beta-protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Age-related macular degeneration

Most Recent Events

  • 09 Nov 2015 Vision Medicines plans a phase II/III trial for Age-related macular degeneration in USA
  • 09 Nov 2015 Phase-I clinical trials in Age-related macular degeneration in USA (IV)
  • 09 Nov 2015 Safety data from two phase I trial in Age-related macular degeneration released by Vision Medicines
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top